Subclinical hypothyroïdismNCT07599241
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
A study testing physical activity in people with Subclinical hypothyroïdism and Non-Alcoholic Fatty Liver Disease, run by Cairo University at 1 site in Egypt.
Trial summary
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated Read more about this study
- Who is it for?
- Ages 65 to 75 years, women only
- Conditions the study is for
- Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma
- What is being tested?
- physical activity
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Mar 2026to 15 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 75 years
- Women only
- No healthy volunteers
- Older adult
Who may be able to join
- subclinical hypothrodism (significant form)
- primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma)
- fatty liver (non alcholic type)
- elder females
Who cannot join
- respiratory issues
- cardiac issues
- renal issues
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Dokki, Giza Governorate, 11432
ali AM Ismail, lecturer, +201005154209, ali.mohamed@pt.cu.edu.eg
About this study
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
Read the detailed description
hypthyroidism elder females (n=40) with glaucoma and fatty liver issues will randomly divided into group number 1 (n=20) that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month or group number II (n=20) that will receive levothyroxine only
- Conditions
- Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma
- Being tested
- physical activity, usual care
- Medical subject headings
- Non-alcoholic Fatty Liver Disease, Glaucoma, Open-Angle
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physical activityBehavioural
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month
usual careOther
hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only
| Study group | Role | What they receive |
|---|---|---|
| group number 1 | Experimental | hypthyroidism elder females (n=20) with glaucoma and fatty liver issues recive their levothyroxine and physical activity program on treadmill thrice weekly for 6 month Receives: Behavioral: physical activity |
| group number 2 | Active comparator | hypthyroidism elder females (n=20) with glaucoma and fatty liver issues will recive their levothyroxine only Receives: Other: usual care |
What is being measured
The primary outcome is the main question the study is designed to answer.
intraocular pressure
it will be assessed in both eyes
Measured: 6 months
Secondary outcomes (13)
body mass index
it will be assessed on empty stomach and bladder
Measured: 6 months
waist circumfrence
it will be assessed by tape at umblical level
Measured: 6 months
systolic blood pressure
it will be assessed by sphygmomanmometer
Measured: 6 months
diastolic blood pressure
it will be assessed by sphygmomanmometer
Measured: 6 months
glaucoma assocaited life quality survey
it is a questionaire evaluates life quality
Measured: 6 months
triglyceridss
it will be assessed in serum
Measured: 6 months
high density lipoproteines
it will be assesed in serum
Measured: 6 months
alanine transamianses
it will be assessed in serum
Measured: 6 months
aspartate trasnamiansses
it will be assessed in serum
Measured: 6 months
physical conclusion of short form survey
it will assess physical quality of lifes of females
Measured: 6 months
Mental conclusion of short form survey
it will assess physical quality of lifes of females
Measured: 6 months
thyroid stimualting horomone
it will be assessed in serum
Measured: 6 months
fasting glycemia value
it will be assessed in serum
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2026
- Study start15 Mar 2026
- Primary completion15 Dec 2026 (estimated)
- Study completion15 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Subclinical hypothyroïdismStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Mohamed Ali ismail, Cairo University
- Investigators
- Ali MA Ismail, lecturer, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07599241
- Sponsor's protocol ID
- IRB000-14233-75
- Status last verified
- May 2026
- First submitted
- 9 May 2026
- Last updated
- 20 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
- ClinicalTrials.gov ID
- NCT07599241
- Acronym / sponsor ID
- IRB000-14233-75
- Conditions
- Subclinical hypothyroïdism, Non-Alcoholic Fatty Liver Disease, Primary Open Angle Glaucoma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 15 Mar 2026 (actual)
- Primary completion
- 15 Dec 2026 (estimated)
- Study completion
- 15 Dec 2026 (estimated)
- First posted
- 20 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
Detailed description
hypthyroidism elder females (n=40) with glaucoma and fatty liver issues will randomly divided into group number 1 (n=20) that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month or group number II (n=20) that will receive levothyroxine only
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group number 1 | Experimental | Behavioral: physical activityhypthyroidism elder females (n=20) with glaucoma and fatty liver issues recive their levothyroxine and physical activity program on treadmill thrice weekly for 6 month |
| group number 2 | Active comparator | Other: usual carehypthyroidism elder females (n=20) with glaucoma and fatty liver issues will recive their levothyroxine only |
Who may qualify
- Ages
- 65 to 75 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- subclinical hypothrodism (significant form)
- primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma)
- fatty liver (non alcholic type)
- elder females
Key exclusion criteria (3 listed)
- respiratory issues
- cardiac issues
- renal issues
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physical activityhypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month | Behavioural | group number 1 |
| usual carehypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only | Other | group number 2 |
Primary outcome
intraocular pressure
Time frame: 6 months
it will be assessed in both eyes
13 secondary outcomes
body mass index
Time frame: 6 months
waist circumfrence
Time frame: 6 months
systolic blood pressure
Time frame: 6 months
diastolic blood pressure
Time frame: 6 months
glaucoma assocaited life quality survey
Time frame: 6 months
triglyceridss
Time frame: 6 months
high density lipoproteines
Time frame: 6 months
alanine transamianses
Time frame: 6 months
aspartate trasnamiansses
Time frame: 6 months
physical conclusion of short form survey
Time frame: 6 months
Mental conclusion of short form survey
Time frame: 6 months
thyroid stimualting horomone
Time frame: 6 months
fasting glycemia value
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
Related trials for Subclinical hypothyroïdism
Recruiting
Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Pancreatic Disease
Not yet recruitingObservational study
Relationship of Noninvasive Assessment of Central BP With 10 Years Atherosclerotic CVD in Subclinical Hypothyroidism
Subclinical hypothyroïdism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali MA Ismail, lecturer principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing physical activity in people with Subclinical hypothyroïdism and Non-Alcoholic Fatty Liver Disease, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali MA Ismail, lecturer (01005154209, ali.mohamed@pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
intraocular pressure (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.